UK Immunotherapy Study: reanalysis by a combined symptom and medication score
File(s)UK22 study re-analysis using CSM.pdf (839.86 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Reanalysis of UK22 subcutaneous immunotherapy trial according to WAO/EAACI recommendations revealed clinically relevant improvements at both doses. Starting at the lower dose should enable efficacy with lower risk of adverse events.
Date Issued
2018-12-01
Date Acceptance
2018-07-31
Citation
Journal of Allergy and Clinical Immunology, 2018, 142 (6), pp.1998-1999.e3
ISSN
0091-6749
Publisher
Elsevier
Start Page
1998
End Page
1999.e3
Journal / Book Title
Journal of Allergy and Clinical Immunology
Volume
142
Issue
6
Copyright Statement
© 2018 American Academy of Allergy, Asthma & Immunology. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/30149039
PII: S0091-6749(18)31193-X
Subjects
Subcutaneous allergen immunotherapy
allergic rhinitis
combined symptom and medication score
grass pollen immunotherapy
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2018-08-24